I am guessing that you are also a medical practitioner or insider, so forgive me if this is incorrect.
It is quite telling that of at least four individuals who have commented on HC and are capable of interpreting clinical research - and appreciating the significance of this in medical practice and broader health care delivery - have all dismissed this "opportunity".
All credit to Montgomery Investment Management for disclosing his source and providing an educated update. Whilst investors are fully entitled to make decisions independently, and their attempts to understand logic/research/oncology are admirable, the comment at 11:36pm might be heeded in future:
I think in general biotech is one area where you particularly need to remember the “don’t invest in anything you don’t understand” rule, and being mindful that there maybe a lot of variables / confounding factors in the trials that may affect the final outcomes that as a lay person you may not be able to be fully across.
SRX Price at posting:
$17.53 Sentiment: None Disclosure: Not Held
